Picture of Biogen logo

BIIB Biogen Share Price

0.000.00%
us flag iconLast trade - 00:00
HealthcareAdventurousLarge CapHigh Flyer

Momentum

Relative Strength (%)
1m-0.1%
3m+47.64%
6m+42.66%
1yr+54.66%
Volume Change (%)
10d/3m+8.62%
Price vs... (%)
52w High-6.54%
50d MA+4.3%
200d MA+29.46%

Growth & Value

12m Forecast RollingIndustryMarket
PE Ratio (f)18.5
PEG Ratio (f)n/a
EPS Growth (f)-6.93%
Dividend Yield (f)n/a
Valuation (ttm)IndustryMarket
Price to Book Value3.29
Price to Tang. Book8.35
Price to Free Cashflow19.31
Price to Sales4.05
EV to EBITDA15.06

Shareholder Activity

TypeBuy / Hold / Sell
Institutions
Directors
Community

Guru Screens

Quality

NameIndustryMarket
Return on Capital11.73%
Return on Equity24.69%
Operating Margin23.68%

Financial Summary

Year End 31st DecUnit201720182019202020212022E2023ECAGR / Avg
Total Revenue$m12,273.913,452.914,377.913,444.610,981.710,068.419,377.44-0.83%
Operating Profitm
Net Profitm
EPS Reported
Diluted Normalised EPS
EPS Growth%-3.43+31.41+38.02-20.8-43.51+17.08-8.37n/a
PE Ratiox
PEG
Profitability
Operating Margin%
ROA%
ROCE%
ROE%
Cashflow
Op. Cashflow ps
Capex ps
Free Cashflow ps
Dividends
Dividend ps
Dividend Growth%
Dividend Yield%
Dividend Coverx
Balance Sheet
Cash etcm
Working Capitalm
NFAm
Net Debtm
Book Valuem
Diluted Weighted Average Sharesm
Book Value ps

Health Trend(F-Score)

12345678910

Bankruptcy Score(Z-Score)

Distress
Cautious
Safe

Earnings Manipulation Risk(M-Score)

Other Ratios

Leverage (ttm)Total- Intang+ Pension
Gross Gearing
Net Gearing
Cash / Assets

Recent History

Latest interim period vs. prior periodIndustryMarket
Sales Growth
EPS Growth
3yr Compound Annual Growth RateIndustryMarket
Sales CAGR
EPS CAGR
DPS CAGR

Graphical History

Revenue
Blurred out image of Revenue chart
Net Income
Blurred out image of Net Income chart
Normalised EPS
Blurred out image of Normalised EPS chart
PE Ratio Range
Blurred out image of PE Ratio Range chart
Dividend Yield Range
Blurred out image of Dividend Yield Range chart

Analyst Forecasts

Price target
( price)
31st Dec 202231st Dec 2023
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change

Analyst Consensus

Strong SellSellHoldBuyStrong Buy

EPS 2022 / 2023

Blurred out image of Biogen EPS forecast chart

Profile Summary

Biogen Inc. is a global biopharmaceutical company. It is focused on discovering, developing and delivering therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. It has a portfolio of medicines to treat multiple sclerosis (MS), spinal muscular atrophy (SMA) and Alzheimer's disease. Its marketed products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS; SPINRAZA for the treatment of SMA; ADUHELM for the treatment of Alzheimer's disease; and FUMADERM for the treatment of severe plaque psoriasis. It also has a collaboration agreement with Genentech, Inc. (Genentech), a member of the Roche Group, with respect to RITUXAN for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL) and other conditions; RITUXAN HYCELA for the treatment of non-Hodgkin's lymphoma and CLL; GAZYVA; OCREVUS; and other potential anti-CD20 therapies, including mosunetuzumab.

Directors

Last Annual
December 31st, 2021
Last Interim
September 30th, 2022
Incorporated
April 1st, 1997
Public Since
September 17th, 1991
No. of Shareholders
479
No. of Employees
9,610
Sector
Pharmaceuticals
Industry
Healthcare
Exchange
us flag iconNASDAQ Global Select Market
Shares in Issue
144,001,404
Blurred out image of a map
Address
225 Binney Street, CAMBRIDGE, 02142
Web
https://www.biogen.com/
Phone
+1 7814642000
Auditors
PricewaterhouseCoopers LLP

BIIB Share Price Performance

Upcoming Events for BIIB

Q4 2022 Biogen Inc Earnings Release

Q1 2023 Biogen Inc Earnings Release

Similar to BIIB

Picture of Abcam logo

Abcam

us flag iconNASDAQ Global Select Market

Picture of Amgen logo

Amgen

us flag iconNASDAQ Global Select Market

Picture of Amphastar Pharmaceuticals logo

Amphastar Pharmaceuticals

us flag iconNASDAQ Global Select Market

Picture of Amryt Pharma logo

Amryt Pharma

us flag iconNASDAQ Global Select Market

Picture of Amylyx Pharmaceuticals logo

Amylyx Pharmaceuticals

us flag iconNASDAQ Global Select Market

FAQ

Or unlock with your email

Or unlock with your email